quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·30d
PRRelease
C4 Therapeutics Inc. logo

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

CCCC· C4 Therapeutics Inc.
Health Care
Original source

Companies

  • CCCC
    C4 Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 2UpdateTD Cowen-
  • Sep 17UpdateBarclays$8.00
  • Sep 15UpdateStephens$6.00
  • Sep 4UpdateGuggenheim$8.00
  • Dec 19UpdateWells Fargo$12.00
  • Nov 18UpdateStephens$4.00

Related

  • SEC1d
    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.
  • SEC14d
    C4 Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • SEC15d
    C4 Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR15d
    C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
  • INSIDER20d
    SEC Form 4 filed by Anderson Kenneth Carl
  • INSIDER20d
    SEC Form 4 filed by Grogan Donna Roy
  • PR45d
    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • PR49d
    Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022